NIMH CHEMICAL SYNTHESIS PROGRAM

镍氢化学合成项目

• 批准号: 2884278
• 负责人: MARY J TANGA
• 金额: $ 77.57万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2884278
• 关键词: chemical information system; chemical registry /resource; drug design /synthesis /production; neuropharmacologic agent; psychopharmacologic agent; radiotracer

The purpose of the NIMH Chemical Synthesis and Drug Supply Program is to synthesize and provide essential compounds that are unavailable from commercial sources to stimulate basic and clinical research relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in primates and humans. The objectives of the contract are to synthesize non-GMP compounds and GMP (Good Manufacturing Practices) compounds. Approximately 20% of the chemical syntheses may constitute proprietary compounds. Compounds synthesized under the contract could include, but are not limited to, psychoactive drugs, selective ligands for CNS receptor subtypes, ion channel modulators, signal transduction agents, peptides, small molecules, radiolabeled ligands for autoradiography or neuroimaging, chemicals, probes, and synthetic intermediates. The Contractor will store and maintain new and existing compounds in the NIMH Chemical Synthesis and Drug Supply Program Inventory, maintain an electronic database of compounds with analytical and technical information, distribute compounds to investigators, and maintain an electronic inventory of shipments. It is anticipated that synthesis requests will be submitted from a variety of sources including NIH- funded research programs, biotechnology companies, small pharmaceutical companies, or other sources. It is expected that the chemicals or drugs synthesized and distributed by this program will provide individual investigators with conceptual leads for basic and clinical studies of the neurobiology and treatment of mental disorders.

NIMH化学合成和药物供应计划的目的是 合成和提供无法获得的必需化合物 从商业来源刺激基础和临床研究 与心理健康相关的领域，如分子药理学 和中枢神经系统受体的信号传递，纵向研究评估 精神活性物质的分子、生化和行为活动 化合物，以及灵长类动物和人类的脑功能成像。这个 该合同的目标是合成非GMP化合物和 GMP(良好制造规范)化合物。约20%的 化学合成可能构成专有化合物。 根据合同合成的化合物可能包括，但不包括 仅限于，精神活性药物，中枢神经系统受体的选择性配体 亚型，离子通道调节剂，信号转导剂， 放射自显影用多肽、小分子、放射性标记配体 或神经成像、化学品、探头和合成中间体。这个 承包商将储存和维护新的和现有的化合物在 NIMH化学合成和药品供应计划库存，维护 化合物电子数据库，具有分析和技术资料 信息，向调查人员分发化合物，并保持 发货的电子库存。预计合成 申请将来自不同的来源，包括NIH- 资助的研究项目、生物技术公司、小公司 制药公司，或其他来源。预计将会有 由本计划合成和分发的化学品或药物将 为个人调查人员提供基本和 神经生物学与精神分裂症治疗的临床研究 精神错乱。